Harnchoowong Saralee, Soponkanaporn Sirisucha, Vilaiyuk Soamarat, Lerkvaleekul Butsabong, Pakakasama Samart
Division of Rheumatology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Front Pediatr. 2022 Sep 6;10:941318. doi: 10.3389/fped.2022.941318. eCollection 2022.
Hemophagocytic lymphohistiocytosis (HLH) is a potentially life-threatening condition. This study aimed to evaluate treatment outcomes and identify prognostic-related factors in Thai children with HLH.
We retrospectively reviewed the medical records of 76 pediatric patients with HLH who were treated at Ramathibodi Hospital between January 2004 and December 2019. Treatment outcomes were defined as early mortality (death within 30 days after diagnosis) and early treatment response (resolution of all clinical features and normalization of at least one HLH-related laboratory parameter within 4 weeks).
The overall mortality rate was 38% (29/76), with an early mortality rate of 45% (13/29). Malignancy-associated HLH had the highest mortality rate (88%), followed by primary HLH (56%). The predictors of early mortality were central nervous system (CNS) involvement [OR 13 (95%CI 2-83), = 0.007] and platelet counts <44 × 10/mm [OR 8 (95%CI 1.3-49), = 0.024]. The predictors of early treatment response were no CNS involvement [OR 6.6 (95%CI 1.5-28.8), = 0.011], platelet counts more than 44 × 10/mm [OR 8 (95%CI 2.1-30.9), = 0.003], and total bilirubin levels <1.8 mg/dL [OR 4 (95%CI 1.1-14.8), = 0.036]. In the mixed-model analysis, platelet counts in non-survivors increased significantly less than those in survivors, with a mean difference in platelet changes between the two groups of 94.6 × 10/mm ( = 0.003).
The independent predictors of early mortality in children with HLH were CNS involvement and low baseline platelet counts. A slow rate of platelet increases during the first week after diagnosis was also associated with mortality.
噬血细胞性淋巴组织细胞增生症(HLH)是一种可能危及生命的疾病。本研究旨在评估泰国HLH患儿的治疗效果并确定预后相关因素。
我们回顾性分析了2004年1月至2019年12月在拉玛蒂博迪医院接受治疗的76例HLH儿科患者的病历。治疗结果定义为早期死亡率(诊断后30天内死亡)和早期治疗反应(所有临床特征消退且至少一项HLH相关实验室参数在4周内恢复正常)。
总死亡率为38%(29/76),早期死亡率为45%(13/29)。恶性肿瘤相关HLH的死亡率最高(88%),其次是原发性HLH(56%)。早期死亡的预测因素是中枢神经系统(CNS)受累[比值比(OR)13(95%置信区间2 - 83),P = 0.007]和血小板计数<44×10⁹/mm³[OR 8(95%置信区间1.3 - 49),P = 0.024]。早期治疗反应的预测因素是无CNS受累[OR 6.6(95%置信区间1.5 - 28.8),P = 0.011]、血小板计数超过44×10⁹/mm³[OR 8(95%置信区间2.1 - 30.9),P = 0.003]以及总胆红素水平<1.8mg/dL[OR 4(95%置信区间1.1 - 14.8),P = 0.036]。在混合模型分析中,非幸存者的血小板计数增加显著低于幸存者,两组血小板变化的平均差异为94.6×10⁹/mm³(P = 0.003)。
HLH患儿早期死亡的独立预测因素是CNS受累和低基线血小板计数。诊断后第一周血小板增加缓慢也与死亡率相关。